Disease · HP_0001737

Pancreatic cysts

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Pancreatic cysts. Diseases, record HP_0001737. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001737

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Pancreatic cysts
Open Targets ID: HP_0001737
Highest stage of its drugs: Phase 3, for 3 of its 4 drugs, from ClinicalTrials.gov

Source Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PACLITAXEL	CHEMBL428647	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
ALCOHOL	CHEMBL545	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE	CHEMBL888	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
CIPROFLOXACIN	CHEMBL8	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets29

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
POLA1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5422	Drugs and targets
POLA2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/23649	Drugs and targets
POLD1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5424	Drugs and targets
POLD2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5425	Drugs and targets
POLD3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/10714	Drugs and targets
POLD4	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/57804	Drugs and targets
POLE	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5426	Drugs and targets
POLE2	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5427	Drugs and targets
POLE3	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/54107	Drugs and targets
PRIM1	DNA polymerase (alpha/delta/epsilon)	1	DNA polymerase (alpha/delta/epsilon) inhibitor	Phase 3	https://conductscience.org/library/genes/5557	Drugs and targets

1 to 10 of 29

See all 29 targets

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01929460	A Pilot Study on the Use of Prophylactic Antibiotics for EUS-guided Pancreatic Cyst Aspiration	Not applicable	26	2015-12-31	Pancreatic Cysts	CIPROFLOXACIN	Its record names the disease	ClinicalTrials.gov
NCT01698710	Endoscopic Abraxane Injection Into Pancreatic Cysts	Not applicable	5	2017-06-21	Pancreatic Cysts	PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT03085004	CHARM II: Chemotherapy for Ablation and Resolution of Mucinous Pancreatic Cysts	Phase 3	75		Pancreatic Cyst, EUS-FNA	ALCOHOL, GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT02213419	Endoscopic Ultrasonography-guided Double Ethanol Lavage for Pancreatic Cysts: a Prospective Cohort Study	Phase 1	40		Pancreatic Mucinous-Cystic Neoplasm	ALCOHOL	Its record names the disease	ClinicalTrials.gov
NCT07529483	Endoscopic Ultrasound-Guided Chemoablation for the Treatment of Pancreatic Cystic Neoplasms	Phase 2	35		Pancreatic Cystic Neoplasm	GEMCITABINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration	0 of 13	0 of 13	26	NCT01929460	Trial comparisons
Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration	0 of 13	0 of 13	26	NCT01929460	Trial comparisons
Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Adverse Drug Reactions	0 of 13	0 of 13	26	NCT01929460	Trial comparisons
Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Number of Patients With Pancreas Cyst Infection After EUS-guided Pancreatic Cyst Aspiration	0 of 13	0 of 13	26	NCT01929460	Trial comparisons
Ciprofloxacin (Standard Group) vs Placebo (Intervention Group): Procedure-related Complications	0 of 13	5 of 13	26	NCT01929460	Trial comparisons
Drug (Standard Group) vs Intervention Group: serious adverse events	0 of 13	1 of 13	26	NCT01929460	Trial comparisons

Papers from its trials0

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

None in this release.

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001737

GET https://conductscience.org/api/diseases/v1/HP_0001737/targets?page=2

API reference For AI assistants